Irritable Bowel Syndrome Treatment Market to Surpass US$ 3,902.9 Million by 2030 - Coherent Market Insights

24 Jun 2022
www.prnewswire.com
CollaborateLicense out/in
SEATTLE, June 24, 2022 /PRNewswire/ -- According to
irritable bowel syndrome treatment market is estimated to be valued at
US$ 1,444.7 million in
2022 and is expected to exhibit a
CAGR of
13.2% during the forecast period
(2022-2030).
Key Trends and Analysis of the Global Irritable Bowel Syndrome Treatment Market:
Major players operating in the market are focusing on conducting workshops to create awareness regarding irritable bowel syndrome, which is expected to drive the market growth over the forecast period. For instance, in May 2018, Allergan plc, a subsidiary of AbbVie Inc., a biopharmaceutical company, and Ironwood Pharmaceuticals, Inc., a healthcare company, announced the launch of the AboutYourGut.com website. The aim of this launch was to help educate sufferers impacted by irritable bowel syndrome with diarrhea (IBS-D), irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), including providing information on condition management.
Request Sample Copy of this Report @ https://www.coherentmarketinsights.com/market-insight/irritable-bowel-syndrome-treatment-market-506
Key Market Takeaways:
The global
irritable bowel syndrome treatment market is expected to exhibit a
CAGR of 13.2% during the forecast period due to the increasing adoption of inorganic strategies such as agreements by the key players in the market. For instance, in May 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, and its partner AbbVie Inc., a biopharmaceutical company, reached an agreement with Teva Pharmaceuticals USA, Inc., a multinational pharmaceutical company. As per the terms of this agreement, Teva Pharmaceuticals USA, Inc., would be granted a license to market its 72 mcg generic version of LINZESS, the first prescribed brand in the U.S. for the treatment of adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), in the U.S. beginning March 31, 2029 (subject to U.S. FDA approval), unless certain limited circumstances, customary for settlement agreements of this nature occur.
Among medical conditions, the IBS-constipation segment is expected to dominate the segment growth over the forecast period, owing to the increased research and development activities by the key players in the market. For instance, in May 2021, 4D pharma plc., a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced positive data from its completed Phase II trial of LBP Blautix, a single strain live biotherapeutic product (LBP), in subjects with irritable bowel syndrome with constipation (IBS-C) or with diarrhea (IBS-D).
On the basis of drug type, the Linaclotide segment is expected to dominate the segment growth over the forecast period, owing to the increasing approvals for linaclotide. For instance, in August 2021, Ironwood Pharmaceuticals, Inc., a healthcare company, announced that the U.S. Food and Drug Administration (FDA) approved a revised label for LINZESS (linaclotide) based on clinical safety data that had been generated in pediatric studies.
Key players operating in the global irritable bowel syndrome treatment market include
Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/506
Detailed Segmentation:
Global Irritable Bowel Syndrome Treatment Market, By Drug Type:
Other
Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:
Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Global Irritable Bowel Syndrome Treatment Market, By Region:
North America
By Country:
U.S.
Canada
Europe
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East & Africa
By Country:
GCC Countries
Israel
South Africa
Rest of Middle East & Africa
Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/506
Find related trending report below:
Short Bowel Syndrome Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter
Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
SOURCE Coherent Market Insights
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.